The 2015 JOBS Act, including Regulation A+, is driving the biotech industry forward. IPO volume in biotech has more than doubled since 2015, now accounting for almost 40% of US IPOs. Biotech companies are getting to their IPOs faster, at higher valuations, and using the money to fund further R&D, and hiring to support it.
Deregulating capital is creating jobs and saving lives.
Deregulating Innovation Capital: The Effects of the JOBS Act on Biotech Startups | CLS Blue Sky Blog
Under the JOBS Act, Congress and the SEC significantly reduced disclosure requirements and compliance costs for newly public companies.
The Effects of the JOBS Act on Biotech Startups
The 2015 JOBS Act, including Regulation A+, is driving the biotech industry forward. IPO volume in biotech has more than doubled since 2015, now accounting for almost 40% of US IPOs. Biotech companies are getting to their IPOs faster, at higher valuations, and using the money to fund further R&D, and hiring to support it.
Deregulating capital is creating jobs and saving lives.
Deregulating Innovation Capital: The Effects of the JOBS Act on Biotech Startups | CLS Blue Sky Blog
Under the JOBS Act, Congress and the SEC significantly reduced disclosure requirements and compliance costs for newly public companies.